Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
OTCMKTS:PMCBD

PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)
Free PMCBD Stock Alerts
$2.10
+0.01 (+0.48%)
(As of 05/17/2024 ET)
Compare
Today's Range
$2.06
▼
$2.16
50-Day Range
$1.95
▼
$2.52
52-Week Range
$5.56
▼
$55.50
Volume
3,176 shs
Average Volume
8,831 shs
Market Capitalization
$3.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChart
PMCBD stock logo

About PharmaCyte Biotech Stock (OTCMKTS:PMCBD)

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

PMCBD Stock Price History

PMCBD Stock News Headlines

March 19, 2024 | investorplace.com
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024
February 22, 2024 | investing.com
PharmaCyte Biotech Inc (PMCB)
October 27, 2023 | ft.com
Exploring beauty’s biotech frontier
May 26, 2023 | seekingalpha.com
PMCB PharmaCyte Biotech, Inc.
May 11, 2023 | marketwatch.com
PharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender Offer
April 28, 2023 | bizjournals.com
Baltimore Biotech News
March 30, 2023 | techcrunch.com
Biotech & Health
October 7, 2022 | finance.yahoo.com
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
September 28, 2022 | finanznachrichten.de
BLACK BIRD BIOTECH INC
July 28, 2022 | finance.yahoo.com
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
July 19, 2022 | apnews.com
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
July 5, 2022 | finance.yahoo.com
IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS
June 2, 2022 | seekingalpha.com
PharmaCyte Biotech announces $10M share buyback program
June 2, 2022 | seekingalpha.com
PharmaCyte Biotech stock rises on $10M stock buyback plan
June 2, 2022 | apnews.com
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
May 23, 2022 | stockhouse.com
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
February 10, 2022 | finance.yahoo.com
PharmaCyte Biotech, Inc. (PMCB)
January 6, 2022 | finance.yahoo.com
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
December 28, 2021 | businesswire.com
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
December 8, 2021 | stockhouse.com
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
November 30, 2021 | businesswire.com
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
November 12, 2021 | finance.yahoo.com
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
September 16, 2021 | feeds.benzinga.com
Why Are PharmaCyte Shares Moving Higher On Thursday?
August 12, 2021 | finance.yahoo.com
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:PMCBD
CUSIP
N/A
CIK
N/A
Web
www.pharmacyte.com
Phone
(917) 595-2850
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,830,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.09%
Return on Assets
-43.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.90
Quick Ratio
4.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,671,000
Free Float
N/A
Market Cap
$3.51 million
Optionable
Not Optionable
Beta
0.27

Key Executives

  • Kenneth L. Waggoner
    Chairman, President, CEO & Secretary
  • Carlos A. Trujillo
    Chief Financial Officer & Director
  • Walter H. Günzburgs
    Chief Scientific Officer
  • Linda S. Sher
    Chief Medical Officer
  • José L. Iglesias
    Chief Medical Officer

Key Competitors

View All Competitors

PMCBD Stock Analysis - Frequently Asked Questions

How have PMCBD shares performed in 2024?

PharmaCyte Biotech's stock was trading at $2.16 at the beginning of 2024. Since then, PMCBD stock has decreased by 2.8% and is now trading at $2.10.
View the best growth stocks for 2024 here.

How do I buy shares of PharmaCyte Biotech?

Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PMCBD) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Biden Nomination CANCELED?
The Freeport Society
Does this make you sick?
Allegiance Gold
Dems have chosen Biden replacement?
Paradigm Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
This Could be Your “Big Money” AI Moment
InvestorPlace